Current materials for bone regeneration are either monolithic and supplied in a rigid predetermined shape or granular and unable to hold a desired shape. Both types of materials are poorly suited for surgical reconstruction of bone tissue because they lack the following characteristics:

• Ability to control the shape and dimensional properties of the graft
• Controlled release of growth factors, proteins, enzymes, antibiotics, and other drugs
• The flexibility, porosity (for greater neo-vascularization), and strength cannot be modulated

Improvement in the products used to treat and speed healing due to bone injury or disease is vital in order to improve healthcare outcomes. Orlumet has fabricated bone grafting scaffolds that address the above mentioned deficiencies of current materials on the market. These advanced scaffolds involve the use of multiple, non-uniform materials, and are assembled in multipart three dimensional structures.Orlumet’s tissue engineering scaffolds have undergone preliminary testing with significant success in the goat animal model, as well as in 33 human subjects under informed consent. Material and production costs for our tissue engineering technology are relatively low. In addition, the technology is robust, scalable,and highly “surgeon friendly.” . All materials utilized in our tissue engineering scaffolds are approved for use by the FDA. Surgeries involving the use of Orlumet’s first generation of tissue engineering scaffolds are shown below:

Thumbnail Image: